PT - JOURNAL ARTICLE AU - Mahalul Azam AU - Rina Sulistiana AU - Martha Ratnawati AU - Arulita Ika Fibriana AU - Udin Bahrudin AU - Syed Mohamed Aljunid TI - Recurrent SARS-CoV-2 RNA positivity after COVID-19: A systematic review and meta-analysis AID - 10.1101/2020.07.19.20157453 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.19.20157453 4099 - http://medrxiv.org/content/early/2020/07/21/2020.07.19.20157453.short 4100 - http://medrxiv.org/content/early/2020/07/21/2020.07.19.20157453.full AB - Background Previous studies reported recurrent SARS-CoV-2 RNA positivity in individuals who had recovered from COVID-19 infections. However, little is known regarding the systematic review of recurrent SARS-CoV-2 RNA positivity. The current study conducted a systematic review and meta-analysis, aimed to estimate the incidence of recurrent SARS-CoV-2 RNA positivity after recovery from COVID-19 and to determine the factors associated with recurrent positivity.Methods We searched the PubMed, MedRxiv, BioRxiv, the Cochrane Library, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry for studies published to June 12, 2020. Studies were reviewed to determine the risk of bias. A random-effects model was used to pool results. Heterogeneity was assessed using I2.Results Fourteen studies of 2,568 individuals were included. The incidence of recurrent SARS-CoV-2 positivity was 14.81% (95% confidence interval [CI]: 11.44–18.19%). The pooled estimate of the interval from disease onset to recurrence was 35.44 days (95% CI: 32.65–38.24 days), and from the last negative to recurrent positive result was 9.76 days (95% CI: 7.31–12.22 days). Patients with younger age (mean difference [MD]=-2.27, 95% CI: -2.95 to -1.80) and a longer initial illness (MD=8.24 days; 95% CI: 7.54 – 8.95; I2=98.9%) were more likely to experience recurrent SARS-CoV-2 positivity, while patients with diabetes (RR=0.52; 95% CI: 0.30-0.90; I2=53%), severe disease (RR=0.54; 95% CI: 0.35-0.84; I2=70%), and a low lymphocyte count (RR=0.58; 95% CI: 0.39 – 0.86; I2=48%) were less likely to experience recurrent SARS-CoV-2 positivity.Conclusions The incidence of recurrent SARS-CoV-2 positivity was 14.81%. The estimated interval from disease onset to repeat positivity was 35.44 days, and the estimated interval from the last negative result to recurrent positive result duration was 9.76 days.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialSystematic review registered in PROSPERO under the ID: CRD42020186306Funding StatementThis work was supported by the Ministry of Research and Technology/ National Research and Innovation Agency, Republic of Indonesia (Grant no. 056/SP2H/LT/DRPM/2020). These funding bodies had no role in the study design, data collection, data analysis, data interpretation, or writing of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Present study is a systematic review, ethical clearance is not needed for the studyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analyzed during this study are included in this published article or any further information could be requested to the correspondent author. https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=186306 SARS-CoV-2Severe acute respiratory syndrome-coronavirus-2COVID-19coronavirus diseases-19SMCSemarang Medical CenterRNAribonucleic acid